Dr. Reddys Laboratories is presently trading at Rs. 2699.00, up by means of nine.50 factors or 0.35% from its preceding remaining of Rs. 2689.50 on the BSE.

The scrip opened at Rs. 2681.00 and has touched a high and occasional of Rs. 2719.00 and Rs. 2668.00 respectively. So a long way 14988 stocks were traded on the counter.

The BSE organization ‘A’ inventory of face fee Rs. 5 has touched a fifty two week excessive of Rs. 2745.00 on 03-Dec-2018 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and occasional of the scrip stood at Rs. 2,719.00 and Rs. 2624.10 respectively. The present day marketplace cap of the business enterprise is Rs. 44627.31 crore.

The promoters retaining in the corporation stood at 26.77%, even as Institutions and Non-Institutions held 44.Sixty six% and 14.73% respectively.

Dr. Reddy’s Laboratories has released Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) shop-brand equal of Prilosec OTC (omeprazole delayed-release) Tablets, 20 mg, inside the United States marketplace as permitted with the aid of america Food and Drug Administration (USFDA). OTC Omeprazole Delayed-Release Tablets, 20 mg, is a proton pump inhibitor used to treat frequent heartburn happening or extra days in keeping with week in adults.

The mixed marketplace of Prilosec OTC and private label omeprazole OTC merchandise had US retail income of about $492 million for the most recent 365 days ending in October 2018 in keeping with IRI. Dr. Reddy’s Omeprazole Delayed-Release Tablets, 20 mg, is available in 14 be counted bottles bought in cartons of 1, 2, or 3 bottles each. Each bottle includes one entire 14-day course of remedy.